BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

WEST

Freeform Search

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term: iodide ion same (radionuclide or contrast agent)

Display: 10 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ Hit List ◉ Hit Count ○ Side by Side ○ Image

Search | Clear | Help | Logout | Interrupt

Main Menu | Show S Numbers | Edit S Numbers | Preferences | Cases

Search History

DATE: Friday, September 27, 2002 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L12	iodide ion same (radionuclide or contrast agent)	6	L12
L11	((424/1.11)!.CCLS.) and iodide ion	4	L11
L10	L9 and ((424/1.11)!.CCLS.)	13	L10
L9	L8 and (radionuclide or contrast agent)	269	L9
L8	l3 same (stable or stabilize or stabilizer or stabilizing)	7350	L8
L7	L6 and (radionuclide or contrast agent)	1	L7
L6	L5 same (stable or stabilize or stabilizer or stabilizing)	189	L6
L5	iodide ion	3402	L5
L4	l2 and l3	2	L4
L3	iodide or iodine or ki	185437	L3
L2	depreotide	3	L2
L1	tc-99m or tc	46135	L1

END OF SEARCH HISTORY

Welcome to STN International! Enter x:x

LOGINID:ssspta1619lxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09  ZDB will be removed from STN
 NEWS  5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
 NEWS  6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
 NEWS  7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03  New e-mail delivery for search results now available
 NEWS 10  Jun 10  MEDLINE Reload
 NEWS 11  Jun 10  PCTFULL has been reloaded
 NEWS 12  Jul 02  FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14  Jul 29  Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30  NETFIRST to be removed from STN
 NEWS 16  Aug 08  CANCERLIT reload
 NEWS 17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08  NTIS has been reloaded and enhanced
 NEWS 19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
 NEWS 20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26  Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03  JAPIO has been reloaded and enhanced
 NEWS 24  Sep 16  Experimental properties added to the REGISTRY file
 NEWS 25  Sep 16  Indexing added to some pre-1967 records in CA/CAPLUS
 NEWS 26  Sep 16  CA Section Thesaurus available in CAPLUS and CA

 NEWS EXPRESS  February 1 CURRENT WINDOWS VERSION IS V6.0d,
               CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

```
  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *


FILE 'HOME' ENTERED AT 08:51:03 ON 27 SEP 2002

=> fil reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 08:51:09 ON 27 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 SEP 2002  HIGHEST RN 455250-99-4
DICTIONARY FILE UPDATES:  25 SEP 2002  HIGHEST RN 455250-99-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> e depreotide/cn
E1            1     DEPRENYL/CN
E2            1     DEPRENYL HYDROCHLORIDE/CN
E3            1 --> DEPREOTIDE/CN
E4            1     DEPRESOSTEROL/CN
E5            1     DEPRESSAN/CN
E6            2     DEPRESSIN/CN
E7            1     DEPRESSIN (IRIDOID)/CN
E8            1     DEPRESSIN (PHARMACEUTICAL)/CN
E9            1     DEPRESSONOL A/CN
E10           1     DEPRESSONOL B/CN
E11           1     DEPRESSOSIDE/CN
E12           1     DEPRESSOSIDE A/CN

=> s e3
L1            1 DEPREOTIDE/CN

=> d

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2002 ACS
RN   161982-62-3  REGISTRY
CN   Cyclo(L-homocysteinyl-N-methyl-L-phenylalanyl-L-tyrosyl-D-tryptophyl-L-
     lysyl-L-valyl), (1.fwdarw.1')-thioether with 3-[(mercaptoacetyl)amino]-L-
     alanyl-L-lysyl-L-cysteinyl-L-lysinamide (9CI)  (CA INDEX NAME)
```

OTHER CA INDEX NAMES:
CN Cyclo(L-homocysteinyl-N-methyl-L-phenylalanyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl), (1.fwdarw.1')-sulfide with 3-[(mercaptoacetyl)amino]-L-alanyl-L-lysyl-L-cysteinyl-L-lysinamide
OTHER NAMES:
CN 84: PN: WO02060491 PAGE: 50 claimed sequence
CN **Depreotide**
CN P 829
FS PROTEIN SEQUENCE; STEREOSEARCH
DR 174510-48-6
MF C65 H96 N16 O12 S2
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, DIOGENES, DRUGNL, DRUGPAT, DRUGUPDATES, PROMT, TOXCENTER, USAN, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



PAGE 1-B



PAGE 1-C



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1962 TO DATE)
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
13 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.96	6.17

STN INTERNATIONAL LOGOFF AT 08:51:39 ON 27 SEP 2002

```
Welcome to STN International!  Enter x:x

LOGINID:ssspta1619lxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09  ZDB will be removed from STN
 NEWS  5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
 NEWS  6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
 NEWS  7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03  New e-mail delivery for search results now available
 NEWS 10  Jun 10  MEDLINE Reload
 NEWS 11  Jun 10  PCTFULL has been reloaded
 NEWS 12  Jul 02  FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14  Jul 29  Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30  NETFIRST to be removed from STN
 NEWS 16  Aug 08  CANCERLIT reload
 NEWS 17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08  NTIS has been reloaded and enhanced
 NEWS 19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
 NEWS 20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26  Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03  JAPIO has been reloaded and enhanced
 NEWS 24  Sep 16  Experimental properties added to the REGISTRY file
 NEWS 25  Sep 16  Indexing added to some pre-1967 records in CA/CAPLUS
 NEWS 26  Sep 16  CA Section Thesaurus available in CAPLUS and CA

 NEWS EXPRESS  February 1 CURRENT WINDOWS VERSION IS V6.0d,
               CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.
```

```
  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *


FILE 'HOME' ENTERED AT 09:18:07 ON 27 SEP 2002

=>  fil reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:18:15 ON 27 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 SEP 2002  HIGHEST RN 455250-99-4
DICTIONARY FILE UPDATES:  25 SEP 2002  HIGHEST RN 455250-99-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s depreotide/cn
L1            1 DEPREOTIDE/CN

=> fil caplus uspatfull biosis embase medline
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         4.38       4.59

FILE 'CAPLUS' ENTERED AT 09:18:38 ON 27 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:18:38 ON 27 SEP 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:18:38 ON 27 SEP 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 09:18:38 ON 27 SEP 2002
COPYRIGHT (C) 2002 Elsevier Science B.V.  All rights reserved.

FILE 'MEDLINE' ENTERED AT 09:18:38 ON 27 SEP 2002
```

```
=> s l1
L2          19 L1

=> dup rem l2
PROCESSING COMPLETED FOR L2
L3          18 DUP REM L2 (1 DUPLICATE REMOVED)

=> s l3 and iodide ion
L4           0 L3 AND IODIDE ION

=> d l3 ibib abs

L3   ANSWER 1 OF 18  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:        2002:594711  CAPLUS
DOCUMENT NUMBER:         137:159312
TITLE:                   Stabilization of radiopharmaceutical compositions
                         using hydrophilic thioethers and hydrophilic
6-hydroxy
                         chromans
INVENTOR(S):             Cyr, John E.; Pearson, Daniel A.
PATENT ASSIGNEE(S):      Diatide, Inc., USA
SOURCE:                  PCT Int. Appl., 64 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2002060491      A2   20020808       WO 2001-US50423  20011024
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
             UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                  US 2000-694992   A1 20001024
                                        US 2000-695360   A1 20001024
                                        US 2000-695494   A1 20001024
AB   Radiopharmaceutical compns. which are stabilized by addn. of a
hydrophilic
     thioether, a hydrophilic 6-hydroxy-chroman deriv., or a mixt. of a
     hydrophilic thioether and a hydrophilic 6-hydroxy-chroman deriv. are
     described.  Several examples are provided demonstrating the stabilizing
     effects of L-methionine, Trolox, or a combination of the two on
     lyophilized kit prepns. contg. 99mTc-labeled depreotide,
     benzodiazepinedione deriv., a glycoprotein IIb/IIa receptor-binding
     peptide, a peptide chelator, a bisamine bisthiol chelator, or other
     peptides.


=> d l3 2 ibib abs

L3   ANSWER 2 OF 18  CAPLUS  COPYRIGHT 2002 ACS
ACCESSION NUMBER:        2001:489224  CAPLUS
DOCUMENT NUMBER:         135:97445
```

TITLE: Method for relieving pain associated with an internal disease site
INVENTOR(S): Luiken, George A.
PATENT ASSIGNEE(S): Fluoro Probe, Inc., USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047512	A2	20010705	WO 2000-US42661	20001206
WO 2001047512	A3	20020502		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-457498 A1 19991208

AB Methods are provided for in vivo administration of a pain-relieving drug, such as a local anesthetic (e.g. lidocaine), to an interior disease site for pain relief at the interior disease site. In the invention pain treatment methods, a subject is administered a targeting construct comprising a biol. compatible pain-relieving agent and a tumor-avid ligand or monoclonal antibody that preponderantly binds to or is taken up by the tissue assocd. with an interior disease site. Administration is by a method other than topical injection or application, such as parenteral injection. Because the pain-relieving agent is delivered by the ligand to the disease site, intractable pain situated in the interior of the body, such as is caused by various tumors, can be managed using a lower level of the pain-relieving agent then is required when the pain-relieving agent is injected in the free state.

=> d l3 3 ibib abs

L3 ANSWER 3 OF 18 USPATFULL
ACCESSION NUMBER: 2001:237454 USPATFULL
TITLE: Method for viewing tumor tissue located within a body cavity
INVENTOR(S): Luiken, M.D., George A., Coronado, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001055566	A1	20011227
APPLICATION INFO.:	US 2001-832297	A1	20010409 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-362805, filed on 28 Jul 1999, GRANTED, Pat. No. US 6284223
Continuation-in-part of Ser. No. US 1998-173190, filed on 15 Oct 1998, PENDING

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GARY CARY WARE & FRIENDENRICH LLP, 4365 EXECUTIVE DRIVE, SUITE 1600, SAN DIEGO, CA, 92121-2189
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
LINE COUNT: 1252
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for in vivo detection of diseased tissue in a subject, such as tumor tissue located in a body opening, by administering to the subject a biologically compatible fluorescing targeting construct that binds to or is specifically taken up by the diseased tissue. The observer directly views fluorescence emanating from the fluorescing targeting construct bound to or taken up by the diseased tissue upon irradiation of the targeting construct with excitation light having at least one wavelength in the range from 401 nm to about 495 nm, but preferably lacking light having a wavelength above about 500 nm, so as to determine the location and/or surface area of the diseased tissue in the subject. Since excitation wavelength does not penetrate through tissue, as is the practice in near IR diagnostics, the diseased or abnormal tissue is exposed to the excitation light either surgically or by means of an endoscopic device. Preferably a filter is used to filter out any wavelengths in the excitation light greater than about 500 nm.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l3 4 ibib abs

L3 ANSWER 4 OF 18 USPATFULL
ACCESSION NUMBER: 2001:173125 USPATFULL
TITLE: Method for viewing diseased tissue located within a body cavity
INVENTOR(S): Luiken, George, Coronado, CA, United States
PATENT ASSIGNEE(S): Fluoro Probe, Inc., Coronado, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6299860	B1	20011009
APPLICATION INFO.:	US 1998-173190		19981015 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: Jones, Dameron L.
LEGAL REPRESENTATIVE: Gray Cary Ware & Freidenrich, Learn, June M.
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
LINE COUNT: 905
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for in vivo detection of tissue associated with a disease state in a subject, such as tissue located in a body opening. In the invention method, the subject is administered a biologically compatible fluorescing targeting construct, the construct is allowed to bind to any target tissue present in the subject, a body part of the

subject suspected of containing the target tissue is irradiated with UV light while extraneous light to the body part is substantially eliminated, and fluorescence emanating from the fluorescing targeting construct bound to the target tissue is detected and visualized by the observer with or without the aid of an endoscope, so as to determine the location and size of the target tissue. The invention methods offer the advantage that diseased or abnormal tissue can be detected at interior body sites with or without the aid of an endoscopic device. Once the diseased or abnormal tissue has been identified, for example in a surgical opening, such tissue can be readily biopsied or excised surgically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l3 5 ibib abs kwic

L3 ANSWER 5 OF 18 USPATFULL

ACCESSION NUMBER:	2001:147442 USPATFULL		
TITLE:	Method for viewing tumor tissue located within a body cavity		
INVENTOR(S):	Luiken, George, Coronado, CA, United States		
PATENT ASSIGNEE(S):	FluoroProbe, Inc., Coronado, CA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6284223	B1	20010904
APPLICATION INFO.:	US 1999-362805		19990728 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-173190, filed on 15 Oct 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Jones, Dameron L.		
LEGAL REPRESENTATIVE:	Gray Cary Ware & Freidenrich LLP, Learn, June M.		
NUMBER OF CLAIMS:	46		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1154		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are provided for in vivo detection of tumor tissue associated with a disease state in a subject, such as tumor tissue located in body opening. In the invention method, the subject is administered a biologically compatible fluorescing targeting construct, the construct is allowed to bind to and/or be taken up by tumor tissue present in the subject, a body part of the subject suspected of containing the tumor tissue is irradiated with UV light while extraneous light to the body part is substantially eliminated, and fluorescence emanating from the fluorescing targeting construct bound to and/or taken up by the tumor tissue is directly viewed by the observer with or without the aid of an endoscope, so as to determine the location and size of the tumor tissue.

The invention methods offer the advantage that diseased or abnormal tissue can be directly viewed at interior body sites with or without the aid of an endoscopic device, and without the use of additional imaging equipment, for example, through a surgical opening to facilitate a procedure of biopsy or surgical excision.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 60-54-8, Tetracycline 63-68-3, Methionine, biological studies
69-78-3
81-88-9 154-17-6, 2-Deoxyglucose 2321-07-5 2543-43-3 2543-43-3D,
oligomeric 22264-50-2, 1-Aminocyclobutane-1-carboxylic acid
51110-01-1, Somatostatin 68181-17-9 72252-96-1 83150-76-9,
Octreotide 106145-13-5 108736-35-2, Lanreotide 115616-51-8
130838-28-7 150243-58-6 150243-59-7 150244-18-1 153177-60-7
160854-54-6 **161982-62-3**, P829 199804-25-6 256504-33-3
256504-34-4 256504-35-5 264596-75-0, P 587
(fluorescence imaging of tumor tissue)

=> d l3 6 ibib abs

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:260081 CAPLUS
DOCUMENT NUMBER: 132:290564
TITLE: Method for viewing tumor tissue located within a body cavity
INVENTOR(S): Luiken, George A.
PATENT ASSIGNEE(S): Fluoro Probe, Inc., USA
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021576	A2	20000420	WO 1999-US21607	19991012
WO 2000021576	A3	20000713		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6299860	B1	20011009	US 1998-173190	19981015
EP 1121158	A2	20010808	EP 1999-956489	19991012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1998-173190 A2 19981015
US 1999-362805 A2 19990728
WO 1999-US21607 W 19991012

AB Methods are provided for in vivo detection of tissue assocd. with a disease state in a subject, such as tumor tissue located in a body opening. In the invention method, the subject is administered a biol. compatible fluorescing targeting construct, the construct is allowed to bind to and/or be taken up by diseased tissue present in the subject, a body part of the subject suspected of contg. the tumor tissue is irradiated in vivo with UV light while extraneous light to the body part is substantially eliminated, and fluorescence emanating from the fluorescing targeting construct bound to and/or taken up by the tumor tissue is directly viewed by the observer with or without the aid of an endoscope, so as to det. the location and size of the tumor tissue. The invention methods offer the advantage that diseased or abnormal tissue can

be directly viewed at interior body sites with or without the aid of an endoscopic device, and without the use of addnl. imaging equipment, for example, through a surgical opening to facilitate a procedure of biopsy or surgical excision.

=> d l3 7 ibib abs

L3 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:390302 CAPLUS
DOCUMENT NUMBER: 133:39965
TITLE: A multicenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules
AUTHOR(S): Blum, Jay; Handmaker, Hirsch; Lister-James, John; Rinne, Neal
CORPORATE SOURCE: NeoTect Solitary Pulmonary Nodule Study Group, CIGNA Healthcare of Arizona, Phoenix, AZ, USA
SOURCE: Chest (2000), 117(5), 1232-1238
CODEN: CHETBF; ISSN: 0012-3692
PUBLISHER: American College of Chest Physicians
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Objective: The affinity of various malignant neoplasms including small cell and non-small cell lung cancer for peptide analogs of somatostatin has been well documented. Depreotide is such an analog and can be complexed with technetium-99m (99mTc depreotide) for optimal imaging properties. Using this radiopharmaceutical, solitary pulmonary nodules (SPN) were previously evaluated in a successful phase II/III trial. The results of the larger multicenter phase III study using 99mTc depreotide to differentiate malignant and benign etiologies in SPN are now presented.
Methods: Patients with SPN .ltoreq. 6 cm on chest radiograph were referred for evaluation. One hundred fourteen individuals who had an absence of a benign pattern of calcification on CT scan, age > 30 yr, and no demonstrable radiog. stability for the prior 2 yr were studied. All underwent single-photon emission CT (SPECT) with 99mTc depreotide and subsequent tissue histol. examn. Three nuclear medicine specialists blinded to histol. findings examd. the SPECT images and scored them as pos. or neg. based on the presence or absence of activity in the radiog. region of the SPN. The final result was detd. by the majority score, which was then compared with the histol. result. Results: Of the 114 individuals studied, 88 had a histol. result compatible with malignant neoplasm. 99mTc depreotide scintigraphy correctly identified 85 of this group, with three false-neg. detns. compared with histol. There were seven false-pos. detns., including six granulomas and one hamartoma. 99mTc depreotide scintigraphy correctly excluded malignancy in 19 of 26 patients with benign histol. findings. The sensitivity of this method was 96.6% with a specificity of 73.1%. Conclusion: 99mTc depreotide scintigraphy is a safe and useful method for the noninvasive evaluation of SPN with a sensitivity and accuracy comparable to that reported for fluorine-18 fluorodeoxyglucose positron emission tomog.
REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l3 8 ibib abs

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:370600 CAPLUS
DOCUMENT NUMBER: 133:249048
TITLE: Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188Re
AUTHOR(S): Zinn, Kurt R.; Buchsbaum, Donald J.; Chaudhuri, Tandra R.; Mountz, James M.; Grizzle, William E.; Rogers, Buck E.
CORPORATE SOURCE: Departments of Radiology, Radiation Oncology, and Pathology, University of Alabama at Birmingham, Birmingham, AL, USA
SOURCE: Journal of Nuclear Medicine (2000), 41(5), 887-895
CODEN: JNMEAQ; ISSN: 0161-5505
PUBLISHER: Society of Nuclear Medicine, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Gene therapy protocols require better modalities to monitor the location and level of transferred gene expression. One potential in vivo mechanism to assess gene expression would be to image the binding of a radiolabeled peptide to a reporter receptor that is expressed in targeted tissues. This concept was tested in a tumor model using a replication-incompetent adenoviral vector encoding the human type 2 somatostatin receptor (Ad5-CMVhSSTr2). Expression of the hSSTr2 reporter was imaged using a radiolabeled, somatostatin-avid peptide (P829). Methods: Bilateral s.c. A427 tumor xenografts were established on the flanks of athymic nude mice. These human-origin, non-small cell lung tumors are normally neg. for hSSTr2 expression. One tumor was injected directly with Ad5-CMVhSSTr2, whereas the second tumor was injected directly with a control Ad5 vector. The mice were injected i.v. 48 h later with P829 peptide that was radiolabeled to high specific activity with 99mTc (half-life, 6 h) or 188Re (half-life, 17 h). Tumors were frozen and evaluated for somatostatin receptor expression using fluorescein-labeled somatostatin. Results: The accumulation of radiolabeled P829 in hSSTr2-expressing tumors was easily visualized by .gamma. camera imaging 3 h after injection. Imaging region of interest analyses and biodistribution studies confirmed a 5- to 10-fold greater accumulation of both radiolabeled P829 peptides in the Ad5-CMVhSSTr2-injected tumors vs. control tumors injected with control Ad5 vectors. Ad5-CMVhSSTr2-injected tumors accumulated 2.5-3.8 percentage injected dose per g 3 h after injection. Only Ad5-CMVhSSTr2-injected tumors expressed somatostatin receptors, as detd. by immunohistochem. Conclusion: These studies show the feasibility of imaging a 99mTc-labeled peptide's binding to a reporter receptor after in vivo gene transfer to tumor cells. The 188Re-labeled peptide worked equally well for this imaging approach and offers the addnl. advantage of energetic .beta. decay with potential therapeutic efficacy. 99mTc and 188Re are generator produced, an advantage for widespread availability and low cost, and both radioisotopes can be imaged with existing, high-resoln. modalities. There

is great potential for using 99mTc-labeled peptides for imaging gene transfer with the hSSTr2 reporter receptor, esp. when the reporter correlates with the expression of therapeutic genes that can be included simultaneously in the gene therapy vector.

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l3 9 ibib abs

L3 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
ACCESSION NUMBER: 1999:704836 CAPLUS
DOCUMENT NUMBER: 131:327610
TITLE: Labeled somatostatin analogs for imaging cardiovascular disease
INVENTOR(S): Dean, Richard T.; Lister-James, John
PATENT ASSIGNEE(S): Diatide, Inc., USA
SOURCE: U.S., 6 pp., Cont.-in-part of U.S. Ser. No. 253,973. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5976496	A	19991102	US 1997-976995	19971124
CA 2191951	AA	19951214	CA 1995-2191951	19950601
CN 1158090	A	19970827	CN 1995-194356	19950601
ZA 9504548	A	19960315	ZA 1995-4548	19950602

PRIORITY APPLN. INFO.: US 1994-253973 A2 19940603

AB The invention provides methods and kits for detecting cardiovascular disease in a living mammal, using a labeled form of a somatostatin analog.
Suitable labels are 123I, 67Ga, 111In and 99mTc. The methods and kits of the invention provide early detection of atherosclerotic plaque, in particular, unstable atherosclerotic plaque, thus allowing therapeutic intervention prior to acute and potentially fatal incidents of cardiovascular disease. Thus, localization and in-vivo imaging of atherosclerotic plaques was carried out in hypercholesteremic rabbits using Tc-99m-labeled somatostatin analogs.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l3 10 ibib abs

L3 ANSWER 10 OF 18 USPATFULL
ACCESSION NUMBER: 1999:113713 USPATFULL
TITLE: Cyclic hexapeptide somatostatin analogues
INVENTOR(S): Dean, Richard T, Bedford, NH, United States
McBride, William, Summit, NJ, United States
Lister-James, John, Bedford, NH, United States
PATENT ASSIGNEE(S): Diatide, Inc., Londonderry, NH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5955426		19990921	
	WO 9604308		19960215	
APPLICATION INFO.:	US 1997-776160		19970630	(8)
	WO 1995-US9276		19950720	
			19970630	PCT 371 date
			19970630	PCT 102(e) date

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-282980, filed on 29 Jul 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
LEGAL REPRESENTATIVE: McDaniels, Patricia A., Noonan, Kevin E.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, and radiodiagnostic reagents and peptides. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radiosiotope, as well as methods for using such peptides for radiodiagnostic and radiotherapeutic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l3 11 ibib abs

L3 ANSWER 11 OF 18 USPATFULL
ACCESSION NUMBER: 1999:88768 USPATFULL
TITLE: Cyclic peptide somatostatin analogs
INVENTOR(S): Dean, Richard T., Bedford, NH, United States
McBride, William, Manchester, NH, United States
Lister-James, John, Bedford, NH, United States
PATENT ASSIGNEE(S): Diatech, Inc., Londonberry, NH, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5932189		19990803	
APPLICATION INFO.:	US 1994-282980		19940729	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jose G.
ASSISTANT EXAMINER: Jones, Dameron
LEGAL REPRESENTATIVE: McDaniels, Patricia A., Noonan, Kevin E.
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 1032
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, and radiodiagnostic reagents and peptides. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods for using such peptides for radiodiagnostic and radiotherapeutic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l3 12 ibib abs

L3 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:110998 CAPLUS
DOCUMENT NUMBER: 130:322394
TITLE: The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules
AUTHOR(S): Blum, Jay E.; Handmaker, Hirsch; Rinne, Neal A.
CORPORATE SOURCE: CIGNA Healthcare of Arizona, Phoenix, AZ, USA
SOURCE: Chest (1999), 115(1), 224-232
CODEN: CHETBF; ISSN: 0012-3692
PUBLISHER: American College of Chest Physicians
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Many neoplasms including small cell cancers more densely express somatostatin-type receptors or more avidly bind somatostatin than granulomatous and other nonmalignant processes. While non-small cell neoplasms of the lung have not yet been shown to demonstrate this receptor expression, previous studies have documented non-small cell lung cancer detection with somatostatin analog scintigraphy. This phenomenon can be conceivably exploited utilizing technetium Tc-99m P829 (P829), a unique low mol. wt. somatostatin-type receptor binding polypeptide radiopharmaceutical. The objective of this study was to det. the ability of P829 scintigraphy to noninvasively differentiate malignant and nonmalignant solitary pulmonary nodules (SPNs). The radiopharmaceutical technetium 99mTc-P829 was utilized for scintigraphy including single photon emission computed tomog. Thirty individuals with indeterminate SPNs of .gtoreq. 1 cm and significant risk factors for primary lung cancer were identified and underwent P829 scintigraphy. Tissue diagnosis was then established by transthoracic needle biopsy specimens. Fourteen subjects demonstrated abnormal P829 scans in the region of the radiog. abnormality. Twelve of this group had biopsy specimens revealing neoplasia. Two subjects with necrotizing granuloma on biopsy specimen had abnormal P829 scans in the region of the nodule. Sixteen subjects had no abnormal P829 tracer uptake in the region of the nodule. Fourteen subjects had benign diagnoses on biopsy specimens. One member of this group with a non-diagnostic biopsy specimen refused thoracotomy and remains radiog. stable at 24 mo of follow-up. One subject with a squamous cell carcinoma demonstrated no P829 activity in the region of the nodule. The specificity of P829 scintigraphy based on transthoracic needle biopsy specimen was 88%. The sensitivity was 93%. P829 scintigraphy correctly identified or excluded malignancy in 27 of 30 subjects. P829 scintigraphy reliably identified or excluded malignancy in radiog. indeterminate solitary pulmonary nodules. The sensitivity and specificity compared favorably with the reported results of F-18 fluorodeoxyglucose positron emission tomog. imaging.

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l3 13 ibib abs

L3 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:273442 CAPLUS
DOCUMENT NUMBER: 129:51472
TITLE: Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829
AUTHOR(S): Virgolini, Irene; Leimer, Maria; Handmaker, Hirsch; Lastoria, Secondo; Bischof, Claudia; Muto, Pietro; Pangerl, Thomas; Gludovacz, Doris; Peck-Radosavljevic, Markus; Lister-James, John; Hamilton, Gerhard; Kaserer, Klaus; Valent, Peter; Dean, Richard
CORPORATE SOURCE: Department of Nuclear Medicine, University of Vienna, Vienna, A-1090, Austria
SOURCE: Cancer Research (1998), 58(9), 1850-1859
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Recent data suggest that somatostatin receptors (SSTRs) are expressed on various tumor cells. High-level expression of SSTR on the tumor cell surface provides the basis for the successful clin. use of radiolabeled ligands for the in vivo localization of tumor sites. We have characterized the in vitro binding properties of the novel SSTR ligand 99mTc-P829 using primary human tumors (carcinoids, breast cancers, intestinal adenocarcinomas, pheochromocytomas, small cell and non-small cell lung cancer, and melanomas; n = 28), various tumor cell lines, and COS7 cells transfected with the human SSTR (hSSTR) subtypes 1, 2, 3, 4, and 5. 99mTc-P829 bound to primary tumor cells and tumor cell lines with high affinity and high capacity. The dissocn. consts. (Kd) ranged between 1 and 20 nM. 99mTc-P829 also bound with high affinity to the transfected hSSTR2 (Kd, 2.5 nM), hSSTR5 (Kd, 2 nM), and hSSTR3 (Kd, 1.5 nM). Binding of 99mTc-P829 to hSSTR3 was found to be displaceable by unlabeled P829/([ReO]-P829), SST-14, and vasoactive intestinal peptide (VIP; IC50, 2 nM) and, less effectively, by Tyr3-octreotide (IC50, 20 nM). In contrast, the binding of 99mTc-P829 to hSSTR2 and hSSTR5 could be displaced by P829/([ReO]-P829) and Tyr3-octreotide but not by VIP. 99mTc-P829 scintigraphy revealed in vivo binding to primary or metastatic tumor sites in seven of eight patients with breast cancer and six of six patients with melanoma. In summary, our data show that 99mTc-P829 binds with high affinity to many different types of primary and cloned tumor cells. Furthermore, our data identify hSSTR2, the VIP acceptor hSSTR3, and hSSTR5 as the resp. target receptors. Because these receptors are frequently expressed at high levels on primary tumor cells, 99mTc-P829 appears to be a promising novel peptide tracer for tumor imaging.

=> d l3 14 ibib abs

L3 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:367653 CAPLUS

DOCUMENT NUMBER: 125:52519
TITLE: Cyclic hexapeptide somatostatin analogs for radiodiagnosis and radiotherapy
INVENTOR(S): Dean, Richard T.; McBride, William; Lister-James, John
PATENT ASSIGNEE(S): Lister-James, John, USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9604308	A1	19960215	WO 1995-US9276	19950720
W: AU, BR, CA, CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5932189	A	19990803	US 1994-282980	19940729
CA 2195395	AA	19960215	CA 1995-2195395	19950720
AU 9531984	A1	19960304	AU 1995-31984	19950720
AU 702917	B2	19990311		
EP 775160	A1	19970528	EP 1995-928109	19950720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1161698	A	19971008	CN 1995-194920	19950720
BR 9508467	A	19971223	BR 1995-8467	19950720
JP 10506880	T2	19980707	JP 1995-506575	19950720
JP 3117218	B2	20001211	JP 1996-506575	19950720
ZA 9506254	A	19960313	ZA 1995-6254	19950727
US 5955426	A	19990921	US 1997-776160	19970630

PRIORITY APPLN. INFO.: US 1994-282980 A2 19940729
WO 1995-US9276 W 19950720
OTHER SOURCE(S): MARPAT 125:52519
AB The invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, and radiodiagnostic reagents and peptides. Specifically, the invention relates to cyclic peptide derivs. and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods for using such peptides for radiodiagnostic and radiotherapeutic purposes. Receptor-binding data are included. Localization and in vivo imaging of somatostatin receptor-expressing tumors in rats are described (no data).

=> d l3 15 ibib abs

L3 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:148249 CAPLUS
DOCUMENT NUMBER: 124:261669
TITLE: Somatostatin Receptor-Binding Peptides Labeled with Technetium-99m : Chemistry and Initial Biological Studies
AUTHOR(S): Pearson, Daniel A.; Lister-James, John; McBride, William J.; Wilson, David M.; Martel, Lawrence J.; Civitello, Edgar R.; Taylor, John E.; Moyer, Brian R.; Dean, Richard T.
CORPORATE SOURCE: Department of Chemistry, Diatech Inc., Londonderry, NH, 03053, USA

SOURCE: Journal of Medicinal Chemistry (1996), 39(7), 1361-71
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis of peptides which possess a high affinity for the somatostatin receptor and contain a chelator for the radionuclide technetium-99m is described. The target compds. were designed such that they would form stable, oxotechnetium(V) chelate complexes in which the site of metal coordination was well defined and remote from the receptor-binding region. Oxorhenium(V) chelate complexes of these peptides were prepd. as nonradioactive surrogates for the technetium complexes. Peptide oxorhenium complexes and Tc-99m complexes eluted closely upon HPLC anal. The receptor-binding affinities of both the free and rhenium-coordinated species were measured in vitro. The binding affinities of the free peptides (Ki's in the 0.25-10 nM range) compared favorably with [DTPA]octreotide (Ki = 1.6 nM), which, as the indium-111 complex, is already approved for somatostatin-type receptor (SSTR)-expressing tumor imaging in the United States and Europe. Furthermore, the rhenium-coordinated peptides had binding affinities which, in many cases, were higher than those of the corresponding free peptides, with several complexes having Ki = 0.1 nM. Some of the more potent SSTR-binding peptides were labeled with technetium-99m and assessed in an in vivo study with tumor-bearing rats. The 99mTc-labeled peptides prepd. in this study should be useful as SSTR-expressing tumor-imaging agents due to their high SSTR-binding affinities, ease of prepn., and, because they are low mol. wt. peptides, expected pharmacokinetics characterized by rapid tracer excretion from the body resulting in high-contrast images.

=> d l3 16 ibib abs

L3 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:426626 CAPLUS
DOCUMENT NUMBER: 125:136537
TITLE: Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides
AUTHOR(S): Vallabhajosula, Shankar; Moyer, Brian R.; Lister-James, John; McBride, Bill J.; Lipszyc, Helena; Lee, Hiram; Bastidas, Diago; Dean, Richard T.
CORPORATE SOURCE: Department Radiology, Mount Sinai Medical Center, New York, NY, 10029, USA
SOURCE: Journal of Nuclear Medicine (1996), 37(6), 1016-1022
CODEN: JNMEAQ; ISSN: 0161-5505
PUBLISHER: Society of Nuclear Medicine
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We report here the results of studies on the in vitro receptor binding affinity, in vivo tumor uptake and biodistribution of two 99mTc-labeled peptides. Peptides P587 and P829 were synthesized by N-.alpha.-Fmoc peptide chem., purified by reversed-phase HPLC and characterized by fast-atom bombardment mass spectrometry. The peptides were labeled with 99mTc by ligand exchange from 99mTc-glucoheptonate. In vitro somatostatin receptors (SSTR)-binding affinities of P587, P829 and their oxorhenium complexes, [DTPA]octreotide and In-[DTPA]octreotide were detd. in an inhibition assay using AR42J rat pancreatic tumor cell membranes and

125I-[Tyr3]somatostatin-14 as the probe. In vivo single- and dual-tracer studies of 99mTc peptides and 111In-[DTPA]octreotide were carried out using Lewis rats bearing CA20948 rat pancreatic tumor implants. Technetium-99m-P587 and 99mTc-P829 of high-specific activity (>60 Ci (2.2 TBq)/mmole) were prepd. in >90% radiochem. yield. P587 and P829 had a Ki = 2.5 nM and 10 nM, resp. [ReO]P587 and [ReO]P829, representing the 99mTc complexes, had Ki = 0.15 nM and 0.32 nM, resp. In comparison, [DTPA]octreotide and In-[DTPA]octreotide had Ki = 1.6 and 1.2 nM, resp. In vivo tumor uptake of 99mTc-P587 and 99mTc-P829 was high (4.1 and 4.9%ID/g at 90 min postinjection compared to 2.9% for 111In-[DTPA]octreotide). Tumor/blood and tumor/muscle ratios at 90 min postinjection were 6 and 33 for 99mTc-P587, 21 and 68 for 99mTc-P829, and 22 and 64 for 111In-[DTPA]octreotide. The high SSTR-binding affinity and high, receptor-specific and saturable in vivo tumor uptake indicate that 99mTc-P587 and 99mTc-P829 are promising radiotracers for the clin. detection of SSTR-expressing tumors and other tissues by 99mTc gamma scintigraphy.

=> d l3 17 ibib abs

L3 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:155533 CAPLUS
DOCUMENT NUMBER: 124:212160
TITLE: Monoamine, diamide, thiol-containing metal chelating agents
INVENTOR(S): Mcbride, William; Dean, Richard T.
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9533497	A1	19951214	WO 1995-US6914	19950601
W: AU, BR, CA, CN, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2191951	AA	19951214	CA 1995-2191951	19950601
AU 9526944	A1	19960104	AU 1995-26944	19950601
AU 707040	B2	19990701		
BR 9507917	A	19970812	BR 1995-7917	19950601
CN 1158090	A	19970827	CN 1995-194356	19950601
EP 804252	A2	19971105	EP 1995-922159	19950601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 10501531	T2	19980210	JP 1995-501181	19950601
ZA 9504548	A	19960315	ZA 1995-4548	19950602

PRIORITY APPLN. INFO.: US 1994-253973 A 19940603
WO 1995-US6914 W 19950601
OTHER SOURCE(S): MARPAT 124:212160
AB The invention relates to reagents useful in prepg. radiolabeled diagnostic and therapeutic agents (radiopharmaceuticals). Specifically, the invention provides such reagents that are monoamine, diamide, and thiol-contg. metal chelators. Methods of making such reagents, and methods of using the radiopharmaceuticals produced therefrom are also

provided.

=> d l3 18 ibib abs

L3 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:465577 CAPLUS
DOCUMENT NUMBER: 122:234388
TITLE: Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses
INVENTOR(S): Dean, Richard T.; McBride, William; Lister-James, John
PATENT ASSIGNEE(S): Diatech, Inc., USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 44
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9500553	A1	19950105	WO 1994-US6274	19940603
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9470990	A1	19950117	AU 1994-70990	19940603
AU 701083	B2	19990121		
EP 720621	A1	19960710	EP 1994-920076	19940603
EP 720621	B1	20010207		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, SE				
AT 199089	E	20010215	AT 1994-920076	19940603
US 6051206	A	20000418	US 1996-592323	19960506

PRIORITY APPLN. INFO.: US 1993-92335 A2 19930715
WO 1993-US6029 A 19930623
US 1993-92355 A 19930715
WO 1994-US6274 W 19940603
OTHER SOURCE(S): MARPAT 122:234388
AB Therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents, are disclosed. Specifically, the invention relates to cyclic peptide derivs. and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling, and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to cyclic peptide derivs. and analogs of somatostatin radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specifically relates to cyclic peptide derivs. and analogs of somatostatin radiolabeled with cytotoxic radioisotopes (e.g. 186Re, 188Re) for use as radiotherapeutic agents. Methods and kits for making, radiolabeling, and using such peptides diagnostically and therapeutically in a mammalian body are also provided. Data for binding of the analogs to

somatostatin receptors is included, as is use in imaging of somatostatin receptor-expressing tumors.

```
=> e manchanda rajesh/au
E1            1     MANCHANDA RACHNA/AU
E2           14     MANCHANDA RAHUL/AU
E3           13 --> MANCHANDA RAJESH/AU
E4            2     MANCHANDA RAMA/AU
E5            1     MANCHANDA RAMAN/AU
E6            5     MANCHANDA RANJIT/AU
E7            1     MANCHANDA RAVINDER KUMAR/AU
E8           13     MANCHANDA ROHIT/AU
E9            1     MANCHANDA ROOPAK/AU
E10          30     MANCHANDA S/AU
E11         295     MANCHANDA S C/AU
E12           1     MANCHANDA S C M/AU

=> s e3
L5           13 "MANCHANDA RAJESH"/AU

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6           13 DUP REM L5 (0 DUPLICATES REMOVED)

=> s l6 and iodid
L7            0 L6 AND IODID

=> s l6 and iodide
L8            0 L6 AND IODIDE

=> s l6 and depreotide
L9            0 L6 AND DEPREOTIDE

=> s l6 and radionuclide
L10           0 L6 AND RADIONUCLIDE

=> s l6 and contrast agent
L11           0 L6 AND CONTRAST AGENT

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    59.94      64.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -8.05      -8.05

STN INTERNATIONAL LOGOFF AT 09:24:33 ON 27 SEP 2002
```